# CQDM

> CQDM is a VC fund in Montreal backing Biotechnology and Health Care. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Montreal, Canada
- Total investments: 8
- Last investment: Jun 2026
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/cqdm
- X (Twitter): https://www.twitter.com/cqdm_canada
- Website: http://www.cqdm.org

CQDM is a drug discovery company that brings together researchers in academia, biotechs and the pharma industry.

## Contacts

5 contacts available for CQDM. Shizune tracks 2 team members at CQDM. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/cqdm?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Grant | $135k–$2M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 75% |
| Health Care | 5 | 63% |
| Therapeutics | 4 | 50% |
| Medical | 3 | 38% |
| Pharmaceutical | 2 | 25% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Grant | 3 | 38% |
| Seed | 2 | 25% |
| Funding Round | 2 | 25% |
| Corporate Round | 1 | 13% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Canada | 6 | 75% |
| United States | 2 | 25% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Diane Gosselin | Chief Executive Officer | 2 | https://shizune.co/investors/profile/diane-gosselin-519b |
| Jesse Paterson | Senior Director, Business Development | 0 | https://shizune.co/investors/profile/jesse-paterson-0b91 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| DropGenie | DropGenie is building connected hardware to automate gene editing. They are accelerating the pace of discovery through the generation of standardized and compatible scientific information. | $3.2M | Seed | Jun 22, 2026 |  |
| Vega BioImaging | Improving prognostic for immunotherapy | $134.8K | Grant | Mar 01, 2025 |  |
| NeuroTracker | With over 40 peer-reviewed studies built upon 20 years of research in neuroscience, NeuroTracker is the World's number one, most scientifically validated Cognitive Training System. Our proven efficacy and patented system have established NeuroTracker as a valuable tool, widely used by clinicians and therapists in neurovision and rehabilitationmarkets.NeuroTracker is designed to uniquely measure and enhance high-level cognitive function of neural networks that govern situational awareness, attention, executive function and cognitive stamina. Used by elite athletes, military special forces, pilots, professional gamers, and students to increase awareness potential for heightened mental performance and improved cognitive ability.NeuroTracker transforms lives, whatever the starting point is. | $2M | Grant | Oct 31, 2024 |  |
| Oragenics | Oragenics is a development-stage company that primarily engages in fighting infectious diseases, including coronaviruses and multidrug-resistant organisms. Its lead product is an intranasal vaccine candidate to provide long-lasting immunity from SARS-CoV-2 and its variants, which cause COVID-19. |  | Grant | Jun 05, 2023 |  |
| Giiant Pharma | Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerabilityand enhanced therapeutic effect. | $12.4M | Seed | May 21, 2021 |  |
| Mesentech | Mesentech is a company focused on treating diseases and medical conditions that relate to bone. They are generating a series of products, from different, but complementary approaches that will effectively address currently difficult to treat conditions.Bone can be one of the most difficult organs to access and treat with medicines. It’s hardsurface and low porosity presents challenges in adequately getting drugs to either the bone surface or to its interior. Treatment often requires administering high doses of a drug over extended periods. Not only is achievement of efficacy compromised, but also side- effects may be more prevalent and can limit treatment effectiveness.Mesentech’s lead technology is a proprietary bone targeting system that can effectively deliver small-molecule and biological drugs to the surface or to the interior of bone. Pre-clinical in-vivo models have confirmed the utility of this technology. | $1.1M | Corporate Round | Jun 22, 2020 |  |
| Encycle Therapeutics | Encycle Therapeutics is a Toronto-based biotech company exploiting a unique platform technology that enables the rapid synthesis of drug-like macrocycles or membrane-permeable nacellins. Nacellins have enormous potential to target intracellular protein-protein interactions, which are largely intractable to small molecule and biologic modulation,and can represent cheaper, oral equivalents to existing biologics (e.g., monoclonal antibodies). Encycle has collaborated with several pharmaceutical companies to complete a screening library of nacellins, many of which are cell-permeable and possess other drug-like properties. The company is also pursuing independent development of nacellins against integrin alpha-4-beta-7 (IBD) and SMURF2 (fibrosis); its lead program seeks to develop orally bioavailable inhibitors of integrin alpha-4-beta-7, which are safer and less immunogenic than marketed and investigational biologics targeting the same protein. | $840K |  | Jun 16, 2015 |  |
| KalGene Pharmaceuticals | KalGene Pharmaceuticals, Inc. is a privately held company working in partnership with many of North America and Europe’s leading clinician-scientists and academic institutions. KalGene is focused on the development of targeted therapeutics and companion diagnostics. Its programs are aimed at improving clinical and survival outcomes through the useof personalized medicine. Personalized medicine seeks to predict which patients will respond to a particular therapy in advance of treatment. This prediction allows physicians to prescribe treatment according to an individual’s specific biological signature, or needs. | $1.5M |  | Jun 08, 2015 |  |

8 of 8 investments shown.

## Co-investors
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund, 2 deals together
- [Brain Canada](https://shizune.co/investors/profile/brain-canada) — VC Fund, 2 deals together
- [Amorchem](https://shizune.co/investors/profile/amorchem) — VC Fund, 1 deal together
- [Amplitude Venture Capital](https://shizune.co/investors/profile/amplitude-venture-capital) — VC Fund, 1 deal together
- [AQC Capital](https://shizune.co/investors/profile/anges-qu%C3%A9bec-capital) — VC Fund, 1 deal together
- [Fonds de solidarité FTQ](https://shizune.co/investors/profile/fonds-de-solidarit-ftq) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund
- [Business Finland](https://shizune.co/investors/profile/tekes) — VC Fund

### Similar country
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund
- [Real Ventures](https://shizune.co/investors/profile/real-ventures) — VC Fund
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund

## Featured in investor lists
- [Biotech VC Funds in Canada](https://shizune.co/investors/biotech-vc-funds-canada)
- [Biotech Investors in Canada](https://shizune.co/investors/biotech-investors-canada)
- [Life Science Investors in Canada](https://shizune.co/investors/life-science-investors-canada)

## FAQ

### What does CQDM invest in?

CQDM invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Grant and Seed stage. Most of the 8 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is CQDM's check size?

CQDM typically joins rounds of $135k–$2M at Grant. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds CQDM participates in.

### How do I contact CQDM?

Public channels for CQDM include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at CQDM?

The team at CQDM includes Diane Gosselin (Chief Executive Officer) and Jesse Paterson (Senior Director, Business Development). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co